Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced HER2-Negative Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05411380
What this trial is testing

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
wang shusen 73
Large-scale testing (Phase 3)Active Not RecruitingNCT07371910
What this trial is testing

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Metastatic Breast CancerHRD-Positive/HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 200
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Early research (Phase 1)Temporarily pausedNCT03970382
What this trial is testing

Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Who this might be right for
Solid Tumor
PACT Pharma, Inc. 21
Not applicableStudy completedNCT05478590
What this trial is testing

Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Who this might be right for
Breast Neoplasms
Pfizer 440
Testing effectiveness (Phase 2)Study completedNCT03025880
What this trial is testing

Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

Who this might be right for
Advanced Breast Cancer
Spanish Breast Cancer Research Group 36
Testing effectiveness (Phase 2)Looking for participantsNCT05190094
What this trial is testing

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

Who this might be right for
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
International Cancer Research Group, United Arab Emirates 80
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Early research (Phase 1)Ended earlyNCT02561832
What this trial is testing

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 15
Not applicableLooking for participantsNCT06993506
What this trial is testing

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
HER2-negative Breast CancerRecurrenceMetastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 500
Testing effectiveness (Phase 2)WithdrawnNCT03841747
What this trial is testing

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Queen Mary University of London
Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Large-scale testing (Phase 3)Looking for participantsNCT05851014
What this trial is testing

GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Genor Biopharma Co., Ltd. 350
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Early research (Phase 1)Active Not RecruitingNCT03616587
What this trial is testing

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 396
Testing effectiveness (Phase 2)Looking for participantsNCT07368998
What this trial is testing

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Large-scale testing (Phase 3)UnknownNCT03423199
What this trial is testing

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Who this might be right for
Breast Neoplasms
National Cancer Center, Japan 180
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Post-approval studies (Phase 4)Study completedNCT02248571
What this trial is testing

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Who this might be right for
Breast Cancer RecurrentHER2/Neu-negative Carcinoma of BreastHormone Receptor Positive Malignant Neoplasm of Breast
iOMEDICO AG 85
Next Page